Eisai Dips Toe Into Chinese Generics With TianYi Buy
This article was originally published in PharmAsia News
Major Japanese innovator Eisai is moving into the Chinese generics sector through the acquisition of the small Chinese firm Liaoning TianYi Biological, in a move it says is designed to tap into strong projected market growth for such products in China.
You may also be interested in...
Takeda’s recent revelation that it had set aside around $450m for a planned M&A transaction in an undisclosed emerging market has triggered speculation about where and how the company might spend its money. Might China be in the mix?
In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.
As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."